#148 - Richard Miller, M.D., Ph.D.: The gold standard for testing longevity drugs: the Interventions Testing Program

The Peter Attia Drive

Peter Attia, MD

Health & Fitness, Medicine, Fitness

4.7 • 7.3K Ratings

🗓️ 8 February 2021

⏱️ 134 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

Richard Miller is a professor of pathology and the Director of the Center for Aging Research at the University of Michigan. He is one of the architects of the NIA-funded Interventions Testing Programs (ITPs) animal study test protocol. In this episode, Rich goes through the results of the long list of molecules tested by the ITP—including rapamycin, metformin, nicotinamide riboside, an SGLT-2 inhibitor called canagliflozin, and more. Many of the discussed outcomes have had surprising outcomes—both positive and negative findings.

We discuss:

Rich’s interest in aging, and how Hayflick’s hypothesis skewed aging research (3:45);
Dispelling the myth that aging can’t be slowed (15:00);
The Interventions Testing Program—A scientific framework for testing whether drugs extend lifespan in mice (29:00);
Testing aspirin in the first ITP cohort (38:45);
Rapamycin: results from ITP studies, dosing considerations, and what it tells us about early- vs. late-life interventions (44:45);
Acarbose as a potential longevity agent by virtue of its ability to block peak glucose levels (1:07:15);
Resveratrol: why it received so much attention as a longevity agent, and the takeaways from the negative results of the ITP study (1:15:45);
The value in negative findings: ITP studies of green tea extract, methylene blue, curcumin, and more (1:24:15);
17α-Estradiol: lifespan effects in male mice, and sex-specific effects of different interventions (1:27:00);
Testing ursolic acid and hydrogen sulfide: rationale and preliminary results (1:33:15);
Canagliflozin (an SGLT2 inhibitor): exploring the impressive lifespan results in male mice (1:35:45);
The failure of metformin: reconciling negative results of the ITP with data in human studies (1:42:30);
Nicotinamide riboside: insights from the negative results of the ITP study (1:48:45);
The three most important takeaways from the ITP studies (1:55:30);
Philosophies on studying the aging process: best model organisms, when to start interventions, which questions to ask, and more (1:59:30);
Seven reasons why pigs can't fly (2:08:00); and
More.

Learn more: https://peterattiamd.com/

Show notes page for this episode: https://peterattiamd.com/RichardMiller

Subscribe to receive exclusive subscriber-only content: https://peterattiamd.com/subscribe/

Connect with Peter on Facebook | Twitter | Instagram.

Transcript

Click on a timestamp to play from that location

0:00.0	Hey everyone, welcome to the Drive Podcast.
0:13.0	I'm your host, Peter Atia.
0:14.8	This podcast, my website, and my weekly newsletter, I'll focus on the goal of translating
0:18.7	the science of longevity into something accessible for everyone.
0:22.4	Our goal is to provide the best content in health and wellness, full stop, and we've assembled
0:27.0	a great team of analysts to make this happen.
0:29.4	If you enjoy this podcast, we've created a membership program that brings you far more
0:33.2	in depth content if you want to take your knowledge of this space to the next level.
0:37.3	At the end of this episode, I'll explain what those benefits are, or if you want to learn
0:41.0	more now, head over to peteratiamd.com forward slash subscribe.
0:46.3	Now without further delay, here's today's episode.
0:49.0	I guess this week is Richard Miller.
0:54.2	Richard is a professor of pathology at the University of Michigan and the director of Michigan's
0:59.2	Paul F. Glenn Center for Aging Research.
1:02.8	He's served on a variety of editorial and advisory positions on behalf of the American
1:06.4	Federation for Aging Research, a FAR, and the National Institutes of Aging, NIA, which
1:11.6	we talk about a little bit.
1:13.1	He's also served as the editor in chief of aging cell.
1:17.2	He's the recipient of the Nathan Shock Award and the Allied Signal Award, the Irving
1:22.4	Wright Award, and an award from the Glenn Foundation along with a number of other awards
1:27.2	for aging research.
1:28.7	Dr. Miller's research focuses on the problems of the basic biologies of aging, mostly in
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Peter Attia, MD, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Peter Attia, MD and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.